Facebook picto   picto linkdink   picto tiwter

News & Media

Dec 19, 2016
Superior Outcomes of Focal Ablatherm-HIFU

EDAP-TMS
EDAP Reports Superior Outcomes of Focal Ablatherm-HIFU Compared to Robotic Radical Prostatectomy Similar Cancer Control at 5 Years, Significantly Less Incidence of Incontinence and Erectile Dysfunction
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the publication of results comparing Ablatherm Focal HIFU with Robotic Radical Prostatectomy. The results of the study have been electronically published in the prestigious peer-reviewed medical Journal of Endourology; the study will subsequently appear in a print edition.

This matched pair analysis of HIFU hemiablation vs robotic assisted laparoscopic prostatectomy was conducted by Professor Roland van Velthoven, Head of the Urology Department at the Institut Bordet Oncology Center in Brussels, Belgium. In this study, 55 patients with unilateral localized prostate cancer were treated using Ablatherm-HIFU and their outcomes were compared 1:1 with patients, having similar clinical criteria but underwent robotic assisted laparoscopic prostatectomy. The matched pair analysis concluded that HIFU was comparable to robotic-assisted radical prostatectomy in the management of prostate cancer and showed HIFU to have significantly better functional outcomes.

Prof. van Velthoven commented: "Clinical outcomes from this comparative study are extremely encouraging as they confirm the efficacy of HIFU focal in the treatment of localized prostate cancer, reporting similar results to radical prostatectomy in terms of cancer control at 5 years. More importantly, the study proves focal HIFU superiority in terms of side effects with significantly higher continence and potency preservation rates at both 1 month and 2 years after the procedure. Focal HIFU is the ideal minimally invasive approach for patients with low risk prostate cancer seeking treatment of their disease while preserving their quality of life".